AAAAAA
Results:
1-21
|
Results: 21
Authors:
SCHILDER RJ
SHEA TC
Citation: Rj. Schilder et Tc. Shea, MULTIPLE CYCLES OF HIGH-DOSE CHEMOTHERAPY FOR OVARIAN-CANCER, Seminars in oncology, 25(3), 1998, pp. 349-355
Authors:
SMITH MR
XIE T
JOSHI I
SCHILDER RJ
Citation: Mr. Smith et al., DEXAMETHASONE PLUS RETINOIDS DECREASE IL-6 IL-6 RECEPTOR AND INDUCE APOPTOSIS IN MYELOMA CELLS/, British Journal of Haematology, 102(4), 1998, pp. 1090-1097
Authors:
OREILLY S
FLEMING GF
BAKER SD
WALCZAK JR
BOOKMAN MA
MCGUIRE WP
SCHILDER RJ
ALVAREZ RD
ARMSTRONG DK
HOROWITZ IR
OZOLS RF
ROWINSKY EK
Citation: S. Oreilly et al., PHASE-I TRIAL AND PHARMACOLOGICAL TRIAL OF SEQUENCES OF PACLITAXEL AND TOPOTECAN IN PREVIOUSLY TREATED OVARIAN EPITHELIAL MALIGNANCIES - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 15(1), 1997, pp. 177-186
Authors:
MALONEY DG
GRILLOLOPEZ AJ
WHITE CA
BODKIN D
SCHILDER RJ
NEIDHART JA
JANAKIRAMAN N
FOON KA
LILES TM
DALLAIRE BK
WEY K
ROYSTON I
DAVIS T
LEVY R
Citation: Dg. Maloney et al., IDEC-C2B8 (RITUXIMAB) ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH RELAPSED LOW-GRADE NON-HODGKINS-LYMPHOMA, Blood, 90(6), 1997, pp. 2188-2195
Authors:
SCHILDER RJ
MILLENSON MM
ENTMACHER M
ROGATKO A
YESLOW G
HALBHERR T
PADAVICSHALLER K
YOUNG RC
SMITH MR
Citation: Rj. Schilder et al., PHASE-II TRIAL OF DEXAMETHASONE (DEX) AND 13-CIS-RETINOIC ACID (CRA) AS FIRST-LINE TREATMENT FOR MULTIPLE-MYELOMA, Blood, 90(10), 1997, pp. 4141-4141
Authors:
SMITH MR
BOYD RL
MINNITTI C
CLYDE J
HOESSLY MC
CORNFELD M
YESLOW G
HALBHERR T
ROGATKO A
SCHILDER RJ
YOUNG RC
MILLENSON MM
Citation: Mr. Smith et al., PHASE-II TRIAL OF FLUDARABINE ALTERNATING WITH INTERFERON (IFN)ALPHA-2B IN LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL), Blood, 90(10), 1997, pp. 861-861
Authors:
SMITH MR
VARTERASIAN M
KARANES C
PEMBERTON P
YESLOW G
HALBHERR T
SCHILDER RJ
MILLENSON MM
ALKATIB AM
Citation: Mr. Smith et al., PHASE-II TRIAL OF PEND CHEMOTHERAPY IN RELAPSED OR REFRACTORY HODGKINS-DISEASE, Blood, 90(10), 1997, pp. 1519-1519
Authors:
GORDON LI
ANDERSEN J
HABERMANN TM
WINTER JN
GLICK J
SCHILDER RJ
CASSILETH P
Citation: Li. Gordon et al., PHASE-I TRIAL OF DOSE-ESCALATION WITH GROWTH-FACTOR SUPPORT IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE AGGRESSIVE LYMPHOMAS - DETERMINATION OF THE MAXIMUM-TOLERATED DOSE OF PROMACE-CYTABOM, Journal of clinical oncology, 14(4), 1996, pp. 1275-1281
Authors:
ALSALEEM T
MILLENSON MM
SCHILDER RJ
SMITH MR
Citation: T. Alsaleem et al., FLOW CYTOMETRIC IMMUNOPHENOTYPING OF PERIPHERAL LYMPHOCYTES IN LYMPHOID NEOPLASMS, Blood, 88(10), 1996, pp. 3442-3442
Authors:
SMITH MR
XIE T
SCHILDER RJ
Citation: Mr. Smith et al., 9-CIS-RETINOIC ACID (RA) PLUS DEXAMETHASONE (DEX) INDUCES APOPTOSIS IN RPMI8226 MYELOMA CELLS VIA ALTERATIONS IN IL-6 IL-6 RECEPTOR (IL-6R)/, Blood, 88(10), 1996, pp. 3600-3600
Authors:
SCHILDER RJ
MILLENSON MM
COIA LR
ALSALEEM T
KESSLER HB
YESLOW G
HALBHERR T
YOUNG RC
SMITH MR
Citation: Rj. Schilder et al., COMBINED-MODALITY TREATMENT OF PATIENTS WITH EARLY CLINICALLY STAGED HODGKINS-DISEASE, Blood, 88(10), 1996, pp. 354-354
Authors:
FIELDS SZ
IGWEMEZIE LN
KAUL S
SCHACTER LP
SCHILDER RJ
LITAM PP
HIMPLER BS
MCALEER C
WRIGHT J
BARBHAIYA RH
LANGER CJ
ODWYER P
Citation: Sz. Fields et al., PHASE I STUDY OF ETOPOSIDE PHOSPHATE (ETOPOPHOS) AS A 30-MINUTE INFUSION ON DAY-1, DAY-3, AND DAY-5, Clinical cancer research, 1(1), 1995, pp. 105-111
Authors:
SCHILDER RJ
Citation: Rj. Schilder, MOLECULAR MARKERS AND STEM-CELL TRANSPLANTS - ARE THEY MADE FOR EACH OTHER - REPLY, Journal of clinical oncology, 13(9), 1995, pp. 2473-2473
Authors:
SCHILDER RJ
Citation: Rj. Schilder, MOLECULAR MARKERS AND STEM-CELL TRANSPLANTS - ARE THEY MADE FOR EACH OTHER, Journal of clinical oncology, 13(5), 1995, pp. 1052-1054
Authors:
HAAS NB
SCHILDER RJ
NASH S
WEINER LM
CATALANO RC
OZOLS RF
ODWYER PJ
Citation: Nb. Haas et al., A PHASE-II TRIAL OF WEEKLY INFUSIONAL 5-FLUOROURACIL IN COMBINATION WITH LOW-DOSE LEUCOVORIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER, Investigational new drugs, 13(3), 1995, pp. 229-233
Authors:
KOTZ KW
SCHILDER RJ
Citation: Kw. Kotz et Rj. Schilder, HIGH-DOSE CHEMOTHERAPY AND HEMATOPOIETIC PROGENITOR-CELL SUPPORT FOR PATIENTS WITH EPITHELIAL OVARIAN-CANCER, Seminars in oncology, 22(3), 1995, pp. 250-262
Authors:
NEGENDANK WG
PADAVICSHALLER KA
LI CW
MURPHYBOESCH J
STOYANOVA R
KRIGEL RL
SCHILDER RJ
SMITH MR
BROWN TR
Citation: Wg. Negendank et al., METABOLIC CHARACTERIZATION OF HUMAN NON-HODGKINS-LYMPHOMAS IN-VIVO WITH THE USE OF PROTON-DECOUPLED PHOSPHORUS MAGNETIC-RESONANCE SPECTROSCOPY, Cancer research, 55(15), 1995, pp. 3286-3294
Authors:
MALONEY DG
GRILLOLOPEZ AJ
BODKIN D
WHITE C
FOON K
SCHILDER RJ
NEIDHART J
JANAKIRAMAN N
WALDICHUK C
DAVIS T
DALLAIRE BK
ROYSTON I
LEVY R
Citation: Dg. Maloney et al., IDEC-C2B8 ANTI-CD20 ANTIBODY - RESULTS OF LONG-TERM FOLLOW-UP OF RELAPSED NHL PHASE-II TRIAL PATIENTS, Blood, 86(10), 1995, pp. 205-205
Authors:
SMITH MR
XIE T
SCHILDER RJ
Citation: Mr. Smith et al., RETINOIC ACIDS (RA) PLUS DEXAMETHASONE (DEX) INHIBIT MULTIPLE-MYELOMACELL-GROWTH VIA ALTERATIONS IN IL-6 IL-6 RECEPTOR (IL-6R)/, Blood, 86(10), 1995, pp. 742-742
Authors:
ALSALEEM T
SCHILDER RJ
MILLENSON M
SMITH MR
Citation: T. Alsaleem et al., RECLASSIFICATION OF LYMPHOID NEOPLASMS INTO NEWLY RECOGNIZED ENTITIESBY FLOW CYTOMETRIC IMMUNOPHENOTYPING, Blood, 86(10), 1995, pp. 2121-2121
Authors:
SCHILDER RJ
LACRETA FP
PEREZ RP
JOHNSON SW
BRENNAN JM
ROGATKO A
NASH S
MCALEER C
HAMILTON TC
ROBY D
YOUNG RC
OZOLS RF
ODWYER PJ
Citation: Rj. Schilder et al., PHASE-I AND PHARMACOKINETIC STUDY OF ORMAPLATIN (TETRAPLATIN, NSC-363812) ADMINISTERED ON A DAY-1 AND DAY-8 SCHEDULE, Cancer research, 54(3), 1994, pp. 709-717
Risultati:
1-21
|